436 related articles for article (PubMed ID: 23543450)
1. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis.
Migliore A; Broccoli S; Massafra U; Cassol M; Frediani B
Eur Rev Med Pharmacol Sci; 2013 Mar; 17(5):658-67. PubMed ID: 23543450
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jansen JP; Bergman GJ; Huels J; Olson M
Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
[TBL] [Abstract][Full Text] [Related]
4. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
6. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.
Mandema JW; Zheng J; Libanati C; Perez Ruixo JJ
J Clin Endocrinol Metab; 2014 Oct; 99(10):3746-55. PubMed ID: 24915115
[TBL] [Abstract][Full Text] [Related]
7. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
9. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
[TBL] [Abstract][Full Text] [Related]
11. How to manage postmenopausal osteoporosis?
Body JJ
Acta Clin Belg; 2011; 66(6):443-7. PubMed ID: 22338309
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
13. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
Bridgeman MB; Pathak R
Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
[TBL] [Abstract][Full Text] [Related]
15. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
[TBL] [Abstract][Full Text] [Related]
16. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
[TBL] [Abstract][Full Text] [Related]
17. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
18. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR; Nicolopoulos K; Stringer D; Ma N; Jenal M; Vreugdenburg T
Calcif Tissue Int; 2023 Jun; 112(6):631-646. PubMed ID: 37016189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]